|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||248.29 - 248.29|
|52-week range||248.29 - 248.29|
|Beta (5Y monthly)||1.45|
|PE ratio (TTM)||118.24|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
RESEARCH TRIANGLE PARK, N.C., July 22, 2021--Digital health tools are increasingly having a positive impact on health outcomes. Some are becoming integral parts of mainstream medicine, according to findings released today by the IQVIA Institute for Human Data Science in a new report, Digital Health Trends 2021: Innovation, Evidence, Regulation, and Adoption.
RESEARCH TRIANGLE PARK, N.C., July 13, 2021--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its second-quarter 2021 financial results before the market opens on Tuesday, July 27, 2021. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.
RESEARCH TRIANGLE PARK, N.C., June 24, 2021--IQVIA™ (NYSE: IQV) today introduced Clinical Data Analytics Suite (CDAS), a new SaaS-based clinical data analytics platform that combines structured and unstructured data from clinical trials into a single, standardized setting for easier access and use. This produces a scalable repository, that helps meet regulatory requirements, for stakeholders to investigate operational and clinical data. It also drives faster predictive analytics using AI/ML, ena